List view / Grid view
21 June 2016 | By Victoria White, Digital Content Producer
The Phase I study will evaluate the ability of UCART19 to induce molecular remission in paediatric patients with relapsed or refractory CD19 positive B-ALL...
13 June 2016 | By Victoria White, Digital Content Producer
Results showed improvement over chemotherapy on a number of measures including complete haematologic remission and progression-free survival...
10 June 2016 | By Victoria White, Digital Content Producer
Amgen's Blincyto (blinatumomab) demonstrated an almost two-times increase in median overall survival compared to standard of care...
7 June 2016 | By Victoria White, Digital Content Producer
Using next-generation sequencing technology, researchers were able to study the genome of cancer cells, which is how they discovered the new cancer types...
2 March 2016 | By Victoria White
The sBLA includes new data supporting the treatment of paediatric and adolescent patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)...
5 February 2016 | By Victoria White
Blincyto is a BiTE antibody construct that binds specifically to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells...
Mega mergers, 3D printed drugs, a call for action on antimicrobial resistance: 2015 certainly was an interesting year for the pharmaceutical industry. Here we pick a selection of the top stories that hit the headlines.
19 January 2016 | By Victoria White
With this authorisation, Oncaspar will provide an important treatment option for more European patients with this rapidly progressing cancer of the white blood cells...
8 December 2015 | By Victoria White
This finding comes from from an ongoing Phase II study of CTL019 and, Novartis says, further support its potential in the treatment of paediatric patients with relapsed/refractory acute lymphoblastic leukaemia...
24 November 2015 | By Victoria White
Blincyto is the first bispecific CD19-directed CD3 T cell engager (BiTE) antibody construct approved in European Union...
19 November 2015 | By Victoria White
Earlier this month, Great Ormond Street Hospital (GOSH) reported that UCART19 had been used treat a one-year-old girl who had relapsed acute lymphoblastic leukaemia...
6 November 2015 | By Victoria White
A team at Great Ormond Street Hospital has used UCART 19 cells to treat a one-year-old girl who had relapsed acute lymphoblastic leukaemia with positive results...
19 October 2015 | By Victoria White
Pfizer’s investigational antibody-drug conjugate inotuzumab ozogamicin has received Breakthrough Therapy designation for acute lymphoblastic leukaemia...
20 July 2015 | By
Amgen has announced the top-line results of a Phase 2 trial evaluating blinatumomab in adults with relapsed or refractory Ph+ B-cell precursor ALL...
Baxter has signed a definitive agreement to acquire the Oncaspar® (pegaspargase) product portfolio from Sigma-Tau for US $900 million.
